Investor Presentaiton
Balanced Revenue Contribution and Robust Growth Profile
19%
RMS
Total
Revenue
61%
DSA
20%
Manufacturing*
Research Models
Research Model Services
Human Cellular Products
(Cell Supply)
9.0%
Organic growth
FY 2022
25.2%
Non-GAAP
operating margin
FY 2022
-
Discovery Services
-
Safety Assessment
17.5%
Organic growth
FY 2022
25.3%
Non-GAAP
operating margin
FY 2022
Microbial Solutions
Biologics Testing
C> CDMO
5.3%
Organic growth
FY 2022
28.8%
Non-GAAP
operating income
FY 2022
Charles River Laboratories (CRL)
See ir.criver.com for reconciliations of GAAP to non-GAAP results.
All revenue and operating income/margin figures based on FY 2022 financial information.
*Note: Charles River completed the previously announced divestiture of the Avian Vaccine business in December 2022. Avian is included in the FY 2022 figures above.
7View entire presentation